Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab regimens for fibrillary glomerulonephritis
NCT06680349Phase 4Completed
- Sponsor
- University of Turin
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in fibrillary glomerulonephritis (FGN) (2 arms), sponsored by University of Turin. Primary endpoint: Renal response at 6 months. Started Dec 2022; status: completed.
02
Drugs
rituximab
03
Conditions
fibrillary glomerulonephritis (FGN)
Beyond the preview
Go deeper on NCT06680349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680349.